Role of toll-like receptors (TLRs) and nucleotide-binding oligomerization domain receptors (NLRs) in viral infections;Papel de los receptores tipo toll (TLRs) y receptores para dominios de oligomerización para la unión a nucleótidos (NLRs) en las infecciones virales

Investigacion Clinica (Venezuela)

Volumn 55, Issue 1, 2014, Pages 61-81

  Durán, Anyelo ^a,b   Álvarez Mon, Melchor ^c   Valero, Nereida ^b  

^a Escuela de Bioanálisis   (Venezuela)

^b UNIVERSIDAD DEL ZULIA   (Venezuela)

^c UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Cell signaling; Immune response; NLRs; TLRs; Viral infections

Indexed keywords

NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR; CARRIER PROTEIN; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CASPASE RECRUITMENT DOMAIN PROTEIN 4; CASPASE RECRUITMENT DOMAIN SIGNALING PROTEIN; CIAS1 PROTEIN, MOUSE; CYTOKINE; NLRP3 PROTEIN, HUMAN;

ARTICLE; HUMAN; IMMUNE RESPONSE; INTRACELLULAR SIGNALING; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; VIRUS INFECTION; ANIMAL; BIOLOGICAL MODEL; BIOSYNTHESIS; CHEMISTRY; CLASSIFICATION; FORECASTING; GENETICS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; INNATE IMMUNITY; MOLECULAR EVOLUTION; MOUSE; MULTIGENE FAMILY; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; REVIEW;

ANIMALS; CARD SIGNALING ADAPTOR PROTEINS; CARRIER PROTEINS; CYTOKINES; EVOLUTION, MOLECULAR; FORECASTING; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; MICE; MODELS, IMMUNOLOGICAL; MULTIGENE FAMILY; NOD1 SIGNALING ADAPTOR PROTEIN; NOD2 SIGNALING ADAPTOR PROTEIN; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; VIRUS DISEASES;

EID: 84900805261     PISSN: 05355133     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (120)

1. Abbas AK, Lichtman AH, Pillai S. Sección I: Introducción al sistema inmunitario: Propiedades generales de las respuestas inmunitarias e inmunidad innata en: Inmunología celular y molecular; 2008, p 3-46. Sección IV: Mecanismos efectores de la respuesta inmunitaria: Citocinas en: Inmunología celular y molecular. Elsiever España, Madrid 6a Edición. p 267-301.
2. Janeway J, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20: 197-216.
3. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010; 11:373-384.
4. Bell JK, Mullen GE, Leifer CA, Mazzoni A, Davies DR, Segal DM. Leucine-rich re-peats and pathogen recognition in Tolllike receptors. Trends Immunol 2003; 24: 528-533.
5. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21:335-376.
6. Bianchi ME. DAMPs, PAMPs and alarmins: All we need to know about danger. J Leukoc Biol 2007; 81(1):1-5.
7. Newton K, Dixit VM. Signaling in innate immunity and inflammation. Cold Spring Harb Perspect Biol 2012; 4: pii: a006049. [doi: 10.1101/cshperspect.a006049]. Available from: URL: http://cshperspectives.cshlp.org/content/4/3/a 0 06049.
8. Lemaitre B, Nicolas E, Michaut L, Reichhart JM and Hoffmann JA. The dorso ventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996; 86:973-983.
9. Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol 2009; 21:317-337.
10. Hornung V, Ablasser A, Charrel-Dennis M, Bauernfeind F, Horvath G, Caffrey DR, Latz E, Fitzgerald KA. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 2009; 458:514-518.
11. Yanai H, Savitsky D, Tamura T, Taniguchi T. Regulation of the cytosolic DNA-sensing system in innate immunity: a current view. Curr Opin Immunol 2009; 21:17-22.
12. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001; 1:135-145.
13. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124:783-801.
14. Matsushima N, Tanaka T, Enkhbayar P, Mikami T, Taga M, Yamada K, Kuroki Y. Comparative sequence analysis of leucinerich repeats (LRRs) within vertebrate toll-like receptors. BMC. Genomics 2007; 8:124. [doi: 10.1186/1471-2164-8-124]. Available from: URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1899181.
15. Roach JC, Glusman G, Rowen L, Kaur A, Purcell MK, Smith KD, Hood L, Aderem A. The evolution of vertebrate Toll-like receptors. Proc. Natl. Acad. Sci. U. S. A. 2005; 102:9577-9582.
16. Botosa I, Segalb D, Daviesa D. The Structural Biology of Toll-Like Receptors, Structure 2011; 19(4): 447-459.
17. Faustin B, Reed JC. Sunburned skin activates inflammasomes. Trends Cell Biol 2008; 18: 4-8.
18. Tattoli I, Travassos LH, Carneiro LA, Magalhaes JG, Girardin SE. The Nodosome: Nod1 and Nod2 control bacterial infections and inflammation. Semin Immunopathol 2007; 29: 289-301.
19. Strober W, Murray PJ, Kitani A, Watanabe T. Signalling pathways and molecular interactions of NOD1 and NOD2. Nat Rev Immunol 2006; 6:9-19.
20. Inohara N, Chamaillard M, McDonald C, Núñez G. NOD-LRR proteins: role in hostmicrobial interactions and inflammatory disease. Annu Rev Biochem 2005; 74:355-383.
21. Ting JP, Lovering RC, Alnemri ES, Bertin J, Boss JM, Davis BK, Flavell RA, Girardin SE, Godzik A, Harton JA, Hoffman HM, Hugot JP, Inohara N, Mackenzie A, Maltais LJ, Nunez G, Ogura Y, Otten LA, Philpott D, Reed JC, Reith W, Schreiber S, Steimle V, Ward PA. The NLR gene family: a standard nomenclature. Immunity 2008; 28(3):285-287.
22. Schroder K, Tschopp J. The inflammasomes. Cell 2010; 140: 821-832.
23. Blasius AL, Beutler B. Intracellular Tolllike receptors. Immunity 2010; 32: 305-315.
24. McGettrick AF, O’Neill LA. Localisation and trafficking of Toll-like receptors: An important mode of regulation. Curr Opin Immunol 2010; 22: 20-27.
25. Lim KH, Staudt LM. Toll-Like Receptor Signaling. Cold Spring Harb Perspect Biol, 2013; 5:a011247. [doi: 10.1101/csh perspect.a011247]. Available from: URL: http://www.ncbi.nlm.nih.gov/pubmed/232 84045.
26. Zhang X, Mosser DM. Macrophage activation by endogenous danger signals. J Pathol 2008; 214:161-178.
27. Ting JP, Duncan JA, Lei Y. How the noninflammasome NLRs function in the innate immune system. Science 2010; 327: 286-290.
28. Barton GM, Kagan JC. A cell biological view of Toll-like receptor function: Regulation through compartmentalization. Nat Rev Immunol 2009; 9:535-542.
29. Morrison DK. MAP kinase pathways. Cold Spring Harb Perspect Biol 2012; 4 (11): pii: a011254. [doi: 10.1101/cshperspect. a011254]. Available from: URL: http://csh perspectives.cshlp.org/content/4/11/a011 254.
30. Hacker H, Tseng PH, Karin M. Expanding TRAF function: TRAF3 as a tri-faced immune regulator. Nat Rev Immunol 2011; 11: 457-468.
31. Flannery S, Bowie AG. The interleukin-1 receptor-associated kinases: Critical regulators of innate immune signalling. Biochem Pharmacol 2010; 80:1981-1991.
32. Casanova JL, Abel L, Quintana-Murci L. Human TLRs and IL-1Rs in host defense: Natural insights from evolutionary, epidemiological, and clinical genetics. Annu Rev Immunol 2011; 29: 447-491.
33. Green NM, Marshak-Rothstein A. Toll-like receptor driven B cell activation in the induction of systemic autoimmunity. Semin Immunol 2011; 23: 106-112.
34. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H, Shaffer AL, Romesser P, Wright G, Powell J, Rosenwald A, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Staudt LM. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011; 470: 115-119.
35. Hennessy EJ, Parker AE, O’Neill LA. Targeting Toll-like receptors: Emerging therapeutics? Nat Rev Drug Discov 2010; 9: 293-307.
36. Takeuchi O, Akira S. Innate immunity to virus infection. Immunol Rev 2009; 227: 75-86.
37. Sabbah A, Chang TH, Harnack R, Frohlich V, Tominaga K, Dube PH, Xiang Y, Bose S. Activation of innate immune antiviral responses by Nod2. Nature Immunology 2009; 10: 1073-1080.
38. Kanneganti TD, Body-Malapel M, Amer A, Park JH, Whitfield J, Franchi L, Taraporewala ZF, Miller D, Patton JT, Inohara N, Núñez G. Critical role for Cryopyrin/Nalp3 in activation of caspase-1 in response to viral infection and doublestranded RNA. J Biol Chem 2006; 281: 36560-36568.
39. Muruve DA, Pétrilli V, Zaiss AK, White LR, Clark SA, Ross PJ, Parks RJ, Tschopp J. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 2008; 452:103-107.
40. Sorensen LN, Reinert LS, Malmgaard L, Bartholdy C, Thomsen AR, Paludan SR. TLR2 and TLR9 synergistically control herpes simplex virus infection in the brain. J Immunol 2008; 181:8604-8612.
41. Zhou S, Halle A, Kurt-Jones EA, Cerny AM, Porpiglia E, Rogers M, Golenbock DT, Finberg RW. Lymphocytic choriomeningitis virus (LCMV) infection of CNS glial cells results in TLR2-MyD88/Mal-dependent inflammatory responses. J Neuroimmunol 2008; 194:70-82.
42. Gaudreault E, Fiola S, Olivier M, Gosselin J. Epstein-Barr virus induces MCP-1 secretion by human monocytes via TLR2. J Virol 2007; 81: 8016-8024.
43. Juckem LK, Boehme KW, Feire AL, Compton T. Differential initiation of innate immune responses induced by human cytomegalovirus entry into fibroblast cells. J Immunol 2008; 180:4965-4977.
44. Murawski MR, Bowen GN, Cerny AM, Anderson LJ, Haynes LM, Tripp RA, Kurt-Jones EA, Finberg RW. Respiratory syncytial virus activates innate immunity through Toll-like receptor 2. J Virol 2009; 83 (3):1492-1500.
45. Zhu J, Martinez J, Huang X, Yang Y. Innate immunity against vaccinia virus is me-diated by TLR2 and requires TLR-independent production of IFN-beta. Blood 2007; 109: 619-625.
46. Dolganiuc A, Oak S, Kodys K, Golenbock DT, Finberg RW, Kurt-Jones E, Szabo G. Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterology 2004; 127:1513-1524.
47. Aravalli RN, Hu S, Lokensgard JR. Inhibition of toll-like receptor signalling in primary murine microglia. J Neuroimmune Pharmacol 2008; 3:5-11.
48. Boehme KW, Guerrero M, Compton T. Human cytomegalovirus envelope glycoproteins B and H are necessary for TLR2 activation in permissive cells. J Immunol 2006; 177: 7094-7102.
49. Bauernfeind F, Hornung V. TLR2 joins the interferon gang. Nat Immunol 2009; 10:1139-1141.
50. Dolganiuc A, Chang S, Kodys K, Mandrekar P, Bakis G, Cormier M, Szabo G. Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-alpha and plasmacytoid dendritic cell loss in chronic HCV infection. J Immunol 2006; 177:6758-6768.
51. Chang S, Dolganiuc A, Szabo G. Toll-like receptors 1 and 6 are involved in TLR2-mediated macrophage activation by hepatitis C virus core and NS3 proteins. J. Leukoc. Biol 2007; 82:479-487.
52. Moriyama M, Kato N, Otsuka M, Shao R, Taniguchi H, Kawabe T, Omata M. Interferon-beta is activated by hepatitis C virus NS5 Band in habited by NS4A, NS4B, and NS5A. Hepatol. Int 2007; 1:302-310.
53. Riordan S, Skinner N, Kurtovic J, Locarnini S, McIver C, Williams R, Visvanathan K. Toll-like receptor expression in chronic hepatitis C: correlation with pro-inflammatory cytokine levels and liver injury. Inflamm. Res 2006; 55:279-285.
54. Wang JP, Zhang Y, Wei X, Li J, Nan XP, Yu HT, Li Y, Wang PZ, Bai XF. Circulating toll-like receptor (TLR) 2, TLR4, and regulatory T cells in patients with chronic hepatitis C. APMIS 2010; 118:261-270.
55. Chung H, Watanabe T, Kudo M, Chiba T. Correlation between hyporesponsiveness to toll-like receptor ligands and liver dysfunction in patients with chronic hepatitis C virus infection. J. Viral Hepat 2011; 18(10): 561-567.
56. Brown R, Gralewski J, Eid A, Knoll B, Finberg R, Razonable R. R753Q single-nucleotide polymorphism impairs toll-like receptor 2 recognition of hepatitis C virus core and non structural 3 proteins. Transplantation 2010; 89: 811-815.
57. Organización Mundial de la Salud (OMS). [Fecha de consulta: 19/03/2011]. Disponible en: http://whqlibdoc.who.int/publications/2009/9789241547871_eng.pdf.
58. Centers for Disease Control and Prevention (CDC). Dengue Homepage. [Fecha de consulta: 12/07/2012]. Disponible en: http://www.cdc.gov/dengue/epidemiology/index.html.
59. Durán A, Bermúdez J, Maldonado MB, Ochoa E, Alcocer S, Levy A, Márquez A, Bermúdez I, Gómez M, Gotera J, Valero N. Incidencia y circulación del virus dengue en el Estado Zulia, Venezuela (2009--2010). Ciencia 2012; 20(1):22-32.
60. Versteeg GA, Garcia-Sastre A. Viral tricks to grid-lock the type I interferon system. Curr Opin Microbiol 2010; 13:508-516.
61. Muñoz-Jordán JL, Laurent-Rolle M, Ashour J, Martínez-Sobrido L, Ashok M, Lipkin WI, García-Sastre A. Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J Virol 2005; 79:8004-8013.
62. Rodriguez-Madoz JR, Belicha-Villanueva A, Bernal-Rubio D, Ashour J, Ayllon J, Fernandez-Sesma A. Inhibition of the type I interferon response in human dendritic cells by dengue virus infection requires a catalytically active NS2B3 complex. J Virol 2010; 84:9760-9774.
63. Chang TH, Chen SR, Yu CY, Lin YS, Chen YS, Kubota T, Matsuoka M, Lin YL. Dengue Virus Serotype 2 Blocks Extracellular Signal-Regulated Kinase and Nuclear Factor-κB Activation to Down regulate Cytokine Production. PLoS ONE 2012; 7(8): e41635. [doi:10.1371/journal.pone. 0041635]. Available from: URL: http://www.plosone.org/article/info%3Adoi%2F1 0.1371%2Fjournal.pone.0041635.
64. Matsumoto M, Seya T. TLR3: interferon induction by double stranded RNA including poly (I:C). Adv Drug Deliv Rev 2008; 60:805-812.
65. Prehaud C, Megret F, Lafage M, Lafon M. Virus infection switches TLR-3-positive human neurons to become strong producers of beta interferon. J Virol 2005; 79:12893-12904.
66. Farina C, Krumbholz M, Giese T, Hartmann G, Aloisi F, Meinl E. Preferential expression and function of Toll-like receptor 3 in human astrocytes. J Neuroimmunol 2005; 159:12-19.
67. Bsibsi M, Ravid R, Gveric D, van Noort JM. Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol 2002; 61:1013-1021.
68. Yoneyama M, Fujita T. Recognition of viral nucleic acids in innate immunity. Rev Med Virol 2010; 20(1):4-22.
69. Edelmann KH, Richardson-Burns S, Alexopoulou L, Tyler KL, Flavell RA, Oldstone MB. Does Toll-like receptor 3 play a biological role in virus infections? Virology 2004; 322:231-238.
70. Gowen BB, Hoopes JD, Wong MH, Jung KH, Isakson KC, Alexopoulou L, Flavell RA, Sidwell RW. TLR3 deletion limits mortality and disease severity due to Phlebovirus infection. J Immunol 2006; 177:6301-6307.
71. Hutchens M, Luker KE, Sottile P, Sonstein J, Lukacs NW, Núñez G, Curtis JL, Luker GD. TLR3 increases disease morbidity and mortality from vaccinia infection. J Immunol 2008; 180:483-491.
72. Le Goffic R, Balloy V, Lagranderie M, Alexopoulou L, Escriou N, Flavell R, Chignard M, Si-Tahar M. Detrimental contribution of the Toll-like receptor (TLR)3 to influenza A virus-induced acute pneumonia. PLoS Pathog 2006; 2:e53. [10. 1371/journal.ppat.0020053]. Available from: URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1475659.
73. Bowie AG, Unterholzner L. Viral evasion and subversion of pattern-recognition receptor signalling. Nat Rev Immunol 2008; 8:911-922.
74. Wang T, Town T, Alexopoulou L, Anderson JF, Fikrig E, Flavell RA. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med 2004; 10:1366-1373.
75. Daffis S, Samuel MA, Suthar MS, Gale MJ, Diamond MS. Toll-like receptor 3 has a protective role against West Nile virus infection. J Virol 2008; 82:10349-10358.
76. Wilson JR, de Sessions PF, Leon MA, Scholle F. West Nile virus nonstructural protein 1 inhibits TLR3 signal transduction. J Viro 2008; 82:8262-8271.
77. Arjona A, Ledizet M, Anthony K, Bonafé N, Modis Y, Town T, Fikrig E. West Nile virus envelope protein inhibits dsRNA-induced innate immune responses. J Immunol 2007; 179:8403-8409.
78. Zhang SY, Jouanguy E, Ugolini S, Smahi A, Elain G, Romero P, Segal D, Sancho-Shimizu V, Lorenzo L, Puel A, Picard C, Chapgier A, Plancoulaine S, Titeux M, Cognet C, von Bernuth H, Ku CL, Casrouge A, Zhang XX, Barreiro L, Leonard J, Hamilton C, Lebon P, Héron B, Vallée L, Quintana-Murci L, Hovnanian A, Rozenberg F, Vivier E, Geissmann F, Tardieu M, Abel L, Casanova JL. TLR3 deficiency in patients with herpes simplex encephalitis. Science 2007; 317:1522-1527.
79. Iwakiri D, Zhou L, Samanta M, Matsumoto M, Ebihara T, Seya T, Imai S, Fujieda M, Kawa K, Takada K. Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signalling from Toll-like receptor 3. J Exp Med 2009; 206:2091-2099.
80. Liang Z, Wu S, Li Y, He L, Wu M, Jiang L, Feng L, Zhang P, Huang X. Activation of Toll-Like Receptor 3 Impairs the Dengue Virus Serotype 2 Replication through Induction of IFN-β in Cultured Hepatoma Cells. PLoS ONE 2011; 6(8):e23346. [doi:10.1371/journal.pone.0023346]. Available from: URL: http://www.plosone.org/article/info%3Adoi%2F10.1371%2F journal.pone.0023346.
81. Wong JP, Christopher ME, Viswanathan S, Karpoff N, Dai X, Das D, Sun LQ, Wang M, Salazar AM. Activation of tolllike receptor signaling pathway for protection against influenza virus infection. Vaccine 2009; 27:3481-3483.
82. Zhou H, Zhao J, Perlman S. Autocrine interferon priming in macrophages but not dendritic cells results in enhanced cytokine and chemokine production after coronavirus infection. MBio 2010; 1(4). pii: e00219-10. [doi: 10.1128/mBio.00219-10]. Available from: URL: http://www. ncbi.nlm.nih.gov/pubmed/20978536.
83. Mazaleuskaya L, Veltrop R, Ikpeze N, Martin-Garcia J, Navas-Martin S. Protective role of Toll-like receptor 3-induced Type I interferon in murine coronavirus infection of macrophages. Viruses 2012, 4:901-923.
84. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA, Walsh EE, Freeman MW, Golenbock DT, Anderson LJ, Finberg RW. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000; 1:398-401.
85. Haynes LM, Moore DD, Kurt-Jones EA, Finberg RW, Anderson LJ, Tripp RA. Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus. J Virol 2001; 75:10730-10737.
86. Hutchens MA, Luker KE, Sonstein J, Nunez G, Curtis JL, Luker GD. Protective effect of Toll-like receptor 4 in pulmonary vaccinia infection. PLoS Pathog 2008; 4: e1000153. [doi:10.1371/journal.ppat. 100 0153]. Available from: URL: http://www.plospathogens.org/article/info%3Adoi%2F 10.1371%2Fjournal.ppat.1000153.
87. Schabbauer G, Luyendyk J, Crozat K, Jiang Z, Mackman N, Bahram S, Georgel P. TLR4/CD14-mediated PI3K activation is an essential component of interferon-dependent VSV resistance in macrophages. Mol Immunol 2008; 45:2790-2796.
88. Okumura A, Pitha PM, Yoshimura A, Harty RN. Interaction between Ebola virus glycoprotein and host toll-like receptor 4 leads to induction of proinflammatory cytokines and SOCS1. J Virol 2010; 84(1): 27-33.
89. Suh HS, Zhao ML, Choi N, Belbin TJ, Brosnan CF, Lee SC. TLR3 and TLR4 are innate antiviral immune receptors in human microglia: role of IRF3 in modulating antiviral and inflammatory response in the CNS. Virology 2009; 392:246-259.
90. Pine SO, McElrath MJ, Bochud PY. Polymorphisms in toll-like receptor 4 and toll-like receptor 9 influence viral load in a seroincident cohort of HIV-1-infected individuals. AIDS 2009; 23:2387-2395.
91. Tal G, Mandelberg A, Dalal I, Cesar K, Somekh E, Tal A, Oron A, Itskovich S, Ballin A, Houri S, Beigelman A, Lider O, Rechavi G, Amariglio N. Association between common Toll-like receptor 4mutations and severe respiratory syncytial virus disease. J Infect Dis 2004; 189:2057-2063.
92. Zhang Y, Lian JQ, Huang CX, Wang JP, Wei X, Nan XP, Yu HT, Jiang LL, Wang XQ, Zhuang Y, Li XH, Li Y, Wang PZ, Robek MD, Bai XF. Over expression of Toll-like receptor 2/4 on monocytes modulates the activities of CD4(+)CD25(+) regulatory T cells in chronic hepatitis B virus infection. Virology 2010; 397(1):34-42.
93. Chen YC, Wang SY, King CC. Bacterial lipopolysaccharide inhibits dengue virus infection of primary human monocytes/macrophages by blockade of virus entry via a CD14-dependent mechanism. J Virol 1999; 73:2650-2657.
94. Cabrera-Hernández A, Thepparit C, Suksanpaisan L, Smith DR. Dengue virus entry into liver (HepG2) cells is independent of hsp90 and hsp70. J Med Virol 2007; 79:386-392.
95. Modhiran N, Kalayanarooj S, Ubol S. Subversion of innate defenses by the interplay between DENV and pre-existing enhancing antibodies: TLRs signalin Collapse. PLoS Negl Trop Dis 4(12): e924. [doi:10.1371/journal.pntd.0000924]. Available from: URL: http://www.plosntds.org/article/info %3Adoi%2F10.1371%2Fjournal.pntd.00009 24.
96. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S. Speciesspecific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004; 303:1526-1529.
97. Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, Gale NW, Iwasaki A, Flavell RA. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci USA 2004; 101 (15):5598-5603.
98. Jurk M, Heil F, Vollmer J, Schetter C, Krieg AM, Wagner H, Lipford G, Bauer S. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 2002; 3(6):499. [doi:10.1038/ni0602-499]. Available from: URL: http://www.nature. com/ni/journal/v3/n6/full/ni0602-499.
99. Gorden KK, Qiu XX, Binsfeld CC, Vasilakos JP, Alkan SS. Cutting edge: activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides. J Immunol 2006; 177:6584-6587.
100. Diebold SS. Recognition of viral single-stranded RNA by Toll-like receptors. Adv Drug Deliv Rev 2008; 60:813-823.
101. Town T, Bai F, Wang T, Kaplan AT, Qian F, Montgomery RR, Anderson JF, Flavell RA, Fikrig E. Toll-like receptor 7 mitigates lethal West Nile encephalitis via interleukin 23-dependent immune cell infiltration and homing. Immunity 2009; 30:242-253.
102. Finberg RW, Wang JP. Antiviral responses: different roles for different tolls. Immunity 2009; 30:173-175.
103. Welte T, Reagan K, Fang H, Machain-Williams C, Zheng X, Mendell N, Chang GJ, Wu P, Blair CD, Wang T. Toll-like receptor 7-induced immune response to cutaneous West Nile virus infection. J Gen Virol 2009; 90 (11):2660-2668.
104. Meier A, Chang JJ, Chan ES, Pollard RB, Sidhu HK, Kulkarni S, Wen TF, Lindsay RJ, Orellana L, Mildvan D, Bazner S, Streeck H, Alter G, Lifson JD, Carrington M, Bosch RJ, Robbins GK, Altfeld M. Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat Med 2009; 15(8):955-959.
105. Oh DY, Baumann K, Hamouda O, Eckert JK, Neumann K, Kücherer C, Bartmeyer B, Poggensee G, Oh N, Pruss A, Jessen H, Schumann RR. A frequent functional toll like receptor 7 polymorphism is associated with accelerated HIV-1 disease progression. AIDS 2009; 23:297-307.
106. Vollmer J, Krieg AM. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev 2009; 61:195-204.
107. Krug A, French AR, Barchet W, Fischer JA, Dzionek A, Pingel JT, Orihuela MM, Akira S, Yokoyama WM, Colonna M. TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity 2004; 21(1): 107-119.
108. Hochrein H, Schlatter B, O’Keeffe M, Wagner C, Schmitz F, Schiemann M, Bauer S, Suter M, Wagner H. Herpes simplex virus type-1 induces IFN-alpha production via Toll-like receptor 9-dependent and-independent pathways. Proc Natl Acad Sci USA 2004; 101:11416-11421.
109. Zhu J, Huang X, Yang Y. Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and-independent pathways. J Virol 2007; 81: 3170-3180.
110. Samuelsson C, Hausmann J, Lauterbach H, Schmidt M, Akira S, Wagner H, Chaplin P, Suter M, O’Keeffe M, Hochrein H. Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. J Clin Invest 2008; 118:1776-1784.
111. Jiang W, Lederman MM, Mohner RJ, Rodriguez B, Nedrich TM, Harding CV, Sieg SF. Impaired naive and memory B-cell responsiveness to TLR9 stimulation in human immunodeficiency virus infection. J Virol 2008; 82:7837-7845.
112. Malaspina A, Moir S, DiPoto AC, Ho J, Wang W, Roby G, O’Shea MA, Fauci AS. CpG oligonucleotides enhance proliferative and effector responses of B Cells in HIV infected individuals. J Immunol 2008; 181:1199-1206.
113. Martinelli E, Cicala C, Van Ryk D, Goode DJ, Macleod K, Arthos J, Fauci AS. HIV-1 gp120 inhibits TLR9-mediated activation and IFN-{alpha} secretion in plasmacytoid dendritic cells. Proc Natl Acad Sci USA 2007; 104:3396-3401.
114. Bochud PY, Hersberger M, Taffé P, Bochud M, Stein CM, Rodrigues SD, Calandra T, Francioli P, Telenti A, Speck RF, Aderem A. Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection. AIDS 2007; 21(4):441-446.
115. Xie Q, Shen HC, Jia NN, Wang H, Lin LY, An BY, Gui HL, Guo SM, Cai W, Yu H, Guo Q, Bao S. Patients with chronic hepatitis B infection display deficiency of plasmacytoid dendritic cells with reduced expression of TLR9. Microbes Infect 2009; 11(4):515-523.
116. Huang X., McCaughan GW, Shackel NA, Gorrell MD. Up-regulation of proproliferative genes and the ligand/receptor pair placental growth factor and vascular endothelial growth factor receptor 1 in hepatitis C cirrhosis. Liver Int 2007; 27:960-968.
117. Schlender J, Hornung V, Finke S, Günthner-Biller M, Marozin S, Brzózka K, Moghim S, Endres S, Hartmann G, Conzelmann KK. Inhibition of toll-like receptor 7-and 9-mediated alpha/beta interferon production in human plasmacytoid dendritic cells by respiratory syncytial virus and measles virus. J Virol 2005; 79: 5507-5515.
118. Plitas G, Burt BM, Nguyen HM, Bamboat ZM, DeMatteo RP. Toll like receptor 9 inhibition reduces mortality in polymicrobial sepsis. J Exp Med 2008; 205:1277-1283.
119. Equils O, Schito ML, Karahashi H, Madak Z, Yarali A, Michelsen KS, Sher A, Arditi M. Toll-like receptor 2 (TLR2) and TLR9 signalling results in HIV-long terminal repeat transactivation and HIV replication in HIV-1 transgenic mouse spleen cells: implications of simultaneous activation of TLRs on HIV replication. J Immunol 2003; 170(10):5159-5164.
120. Wang JP, Bowen GN, Padden C, Cerny A, Finberg RW, Newburger PE, Kurt-Jones EA. Toll-like receptor-mediated activation of neutrophils by influenza A virus. Blood 2008; 112(5):2028-2034.